Nivonirina Robinot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nivonirina Robinot has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Gsur
Center for Cancer Research, Medical University of Vienna, Vienna, Austria
1 shared publication - Andreas Baierl
Austrian Institute for Family Studies, University of Vienna
1 shared publication - Augustin Scalbert
International Agency for Research on Cancer (IARC) Lyon France
1 shared publication - Cornelia M. Ulrich
Huntsman Cancer Institute and Department of Population Health Sciences, University of Utah, Salt Lake City, Utah
1 shared publication - Dieuwertje E. Kok
Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands
1 shared publication - Gernot Leeb
Department of Internal Medicine, Hospital Oberpullendorf, 7350 Oberpullendorf, Austria
1 shared publication
Latest Publications
- Open Access
- 19 February 2021
- Published by MDPI AG in Metabolites
- Vol. 11 (2) , 119
Untargeted Metabolomics Reveals Major Differences in the Plasma Metabolome between Colorectal Cancer and Colorectal Adenomas
Sporadic colorectal cancer is characterized by a multistep progression from normal epithelium to precancerous low-risk and high-risk adenomas to invasive cancer. Yet, the underlying molecular mechanisms of colorectal carcinogenesis are not completely understood. Within the “Metabolomic profiles throughout the continuum of colorectal cancer” (MetaboCCC) consortium we analyzed data generated by untargeted, mass spectrometry-based metabolomics using plasma from 88 colorectal cancer patients, 200 patients with high-risk adenomas and 200 patients with low-risk adenomas recruited within the “Colorectal Cancer Study of Austria” (CORSA). Univariate logistic regression models comparing colorectal cancer to adenomas resulted in 442 statistically significant molecular features. Metabolites discriminating colorectal cancer patients from those with adenomas in our dataset included acylcarnitines, caffeine, amino acids, glycerophospholipids, fatty acids, bilirubin, bile acids and bacterial metabolites of tryptophan. The data obtained discovers metabolite profiles reflecting metabolic differences between colorectal cancer and colorectal adenomas and delineates a potentially underlying biological interpretation.
- 19 February 2021
- Published by MDPI AG in Metabolites
- Vol. 11 (2) , 119
Open AccessUntargeted Metabolomics Reveals Major Differences in the Plasma Metabolome between Colorectal Cancer and Colorectal Adenomas
Sporadic colorectal cancer is characterized by a multistep progression from normal epithelium to precancerous low-risk and high-risk adenomas to invasive cancer. Yet, the underlying molecular mechanisms of colorectal carcinogenesis are not completely understood. Within the “Metabolomic profiles throughout the continuum of colorectal cancer” (MetaboCCC) consortium we analyzed data generated by untargeted, mass spectrometry-based metabolomics using plasma from 88 colorectal cancer patients, 200 patients with high-risk adenomas and 200 patients with low-risk adenomas recruited within the “Colorectal Cancer Study of Austria” (CORSA). Univariate logistic regression models comparing colorectal cancer to adenomas resulted in 442 statistically significant molecular features. Metabolites discriminating colorectal cancer patients from those with adenomas in our dataset included acylcarnitines, caffeine, amino acids, glycerophospholipids, fatty acids, bilirubin, bile acids and bacterial metabolites of tryptophan. The data obtained discovers metabolite profiles reflecting metabolic differences between colorectal cancer and colorectal adenomas and delineates a potentially underlying biological interpretation.